Navigation Links
Heart Devices Not Tested Enough in Women: Study
Date:3/1/2011

By Steven Reinberg
HealthDay Reporter

TUESDAY, March 1 (HealthDay News) -- On top of criticism that the U.S. Food and Drug Administration approves medical devices with too little oversight comes another troubling finding: Many heart-related devices win FDA approval without being adequately tested on women, despite an agency directive to do so.

This means that heart valves, pacemakers, defibrillators and stents get implanted in women without evidence that they benefit this population, researchers from the University of California, San Francisco say.

"We do not know if a lot of medical devices currently on the market are as safe and effective in women as they are in men," said lead researcher Dr. Rita F. Redberg, a professor of medicine and director of Women's Cardiovascular Services at the university and a member of the FDA Circulatory System Devices Panel.

"The FDA needs to turn away device applications that don't have a gender-bias statement," said Redberg, senior author of the study, published online March 1 in Circulation: Cardiovascular Quality and Outcomes.

Differences in size and bleeding tendencies can affect the way these devices operate in men and women, and side effects can also vary by gender, Redberg said.

Recognizing those distinctions, in 1994 the FDA mandated that manufacturers of new medical devices provide statements that the devices were tested in men and women in the same proportion as men and women experiencing the condition that the device would treat, Redberg said.

The data is also supposed to include any safety or effectiveness problems seen in women using the device.

Redberg's team looked at 123 studies submitted with premarket approval applications for 78 high-risk cardiovascular devices, including heart valves and implanted defibrillators. All the devices were approved by the FDA between 2000 and 2007.

During that period, a time when women's heart disease was gaining unprecedented attention, there was no increase in the proportion of women participating in studies or the number of applications with gender-bias statements, Redberg said.

FDA summaries of 28 percent of the studies made no mention of gender. Of those that did, men made up 67 percent of the study participants, the researchers found.

In addition, only 41 percent of the studies included the required gender statement. Of these, 94 percent showed results by sex, and 26 percent found sex-related differences in the safety and effectiveness, the researchers found.

Only 11 percent of the studies without gender-bias statements included any performance data related to gender difference. Studies of fewer than 50 patients were not included in the sex-based analysis, the authors noted.

Among applications the agency approved, device makers erroneously excluded women from studies, the researchers found. Some manufacturers understated the number of women with a specific heart condition. Other times, they said their study included an equivalent number of women as earlier studies, without acknowledging that those prior studies included only a token number of women.

Since data are not available about devices that the FDA didn't approve, Redberg's team couldn't determine how many of these included gender data.

The FDA, meanwhile, says it is working to correct these shortcomings.

"The findings reported in this study are not new," said FDA spokeswoman Karen Riley. "FDA is aware of the under-representation of women in clinical trials," she added.

Recently, the FDA division that approves medical devices has come under fire from the medical community for approving devices too fast without proper data, while device manufacturers complain it doesn't approve devices fast enough and over-complicates the process.

The agency's own 2009 study found that women, children and minorities were underrepresented in premarket cardiovascular clinical trials. "Women were less often enrolled in the studies than men (33.9 percent versus 66.1 percent)," Riley said.

The agency will issue guidance on gender this year, Riley added. "Interim policy improvements are already under way, intended to address the need for greater consistency in sex-specific analysis and availability of sex-specific information for approved medical devices," she said.

Commenting on the study, Dr. Nieca Goldberg, director of the Women's Heart Program at NYU Langone Medical Center in New York City, said more must be done on women's behalf.

"There has to be greater oversight," Goldberg said. "We have to meet the needs and expectations of women."

A woman needs to ask her doctor about the risks and benefits of these devices, Goldberg said.

"But we can't stop women from having these procedures if they really meet the indications," she said.

Redberg, who was speaking independently of her role with the FDA, says stricter enforcement of guidelines is needed.

More information

For more information on women and heart disease, visit the American Heart Association.

SOURCES: Rita F. Redberg, M.D., M.Sc., professor, medicine, and director, Women's Cardiovascular Services, University of California, San Francisco; Karen Riley, M.P.H., spokeswoman, U.S. Food and Drug Administration; Nieca Goldberg, M.D., director, Women's Heart Program, NYU Langone Medical Center, New York City; March 1, 2011, Circulation: Cardiovascular Quality and Outcomes, online


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. ICU Patients at Risk for Rare Heart Rhythm Problem
2. Cook With Love This Valentines Day With Heart-Smart Recipes
3. Study finds racial gaps continue in heart disease awareness
4. Highmark Foundation Awards $120,000 to the American Heart Association
5. Womens Heart Disease Awareness Still Lacking
6. American Heart Association Rapid Access Journal Report: Study Finds Racial Gaps Continue in Heart Disease Awareness, Low Knowledge of Heart Attack Warning Signs Among Women
7. Migraine Linked to Increased Heart Attack Risk
8. PERSONALABS Offers Discounted Healthy Heart Online Blood Tests in February
9. Compound shows promise against intractable heart failure
10. New American Heart Association Survey Finds Heart Disease and Stroke Patients Face Significant Barriers in Obtaining Quality, Affordable Care
11. Ex-President Clinton Undergoes Heart Procedure
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Heart Devices Not Tested Enough in Women: Study 
(Date:2/5/2016)... ... February 05, 2016 , ... Looking for a last-minute Valentine’s Day ... tips of your toes. Foot massage, whether administered by a professional masseuse or a ... The American Board of Multiple Specialties in Podiatry (ABMSP) has taken the ...
(Date:2/5/2016)... ... February 05, 2016 , ... ... from across the country gathered at the La Valencia Hotel in San Diego, ... PROSHRED Chicago was named the year’s most outstanding franchise, walking away with the ...
(Date:2/5/2016)... ... February 05, 2016 , ... Pivot ... 2015 Best in KLAS: Software & Services for HIT Implementation Support & Staffing ... report independently ranks vendor performance by healthcare executives, managers and clinicians representing over ...
(Date:2/5/2016)... ... February 05, 2016 , ... Colorize is a ... drop zone to the next using Colorize's dynamic moving camera. Colorize is perfect for ... includes a 3D slideshow environment with 1 to 5 focus points per scene, stage ...
(Date:2/5/2016)... ... , ... Calls Blacklist has just been updated by mobile app developer Vlad ... has fixed known bugs within the app. Calls Blacklist allows its users to only ... any of their device’s battery power or memory. It provides a powerful call blocker ...
Breaking Medicine News(10 mins):
(Date:2/5/2016)... WARSAW, Ind. , Feb. 5, 2016  Zimmer ... the pricing of the previously announced underwritten secondary offering ... of its stockholders, consisting of affiliates of Blackstone and ... public at an initial price of $96.45 per share. ... of the offering.  Neither Zimmer Biomet nor any of ...
(Date:2/5/2016)... France , Germany , Italy ... ). It includes a 10-year epidemiology forecast for the total prevalent ... sex in these markets. GD epidemiology report is written and developed by ... and market-driven, providing expert analysis of disease trends in the 7MM. ... Italy , Spain , UK, and ...
(Date:2/4/2016)... Feb. 4, 2016  The Senior Care Pharmacy ... Reform Committee Chairman Jason Chaffetz (R-UT) ... today,s hearing , "Developments in the Prescription ... and growing questions about abusive pharmacy benefit manager ... (R-UT) and Ranking Member Elijah Cummings (D-MD) are ...
Breaking Medicine Technology: